Taxane

DRUG14 trials

Sponsors

New Mexico Cancer Research Alliance, Morphotek, Hoffmann-La Roche, Yonsei University, EpicentRx, Inc.

Conditions

Advanced Breast CancerBreast CancerBreast Cancer; HER2-positive; MetastaticBreast NeoplasmsCarcinoma, Non-Small-Cell LungCervical CancerDocetaxelER-Negative PR-Negative HER2-Negative Breast Cancer

Phase 1

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

RecruitingNCT07158918

ABL Bio, Inc.Solid Tumors

Start: 2025-08-06End: 2027-12-02Target: 65Updated: 2025-09-08

Phase 2

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

TerminatedNCT01641939

Hoffmann-La RocheGastric Cancer

Start: 2012-09-03End: 2016-04-30Updated: 2017-05-12

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

CompletedNCT02489903

EpicentRx, Inc.Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer +1

Start: 2015-06-30End: 2021-12-06Updated: 2025-03-17

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

WithdrawnNCT02651610

Peregrine PharmaceuticalsMetastatic Breast Cancer

Start: 2015-12-31End: 2018-06-30Updated: 2017-07-11

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

WithdrawnNCT02685306

Peregrine PharmaceuticalsBreast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Neoplasms +4

Start: 2016-03-31End: 2017-09-30Updated: 2017-03-09

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruitingNCT04293393

Spanish Breast Cancer Research GroupEarly Breast Cancer

Start: 2020-10-02End: 2033-02-28Updated: 2026-03-12

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

RecruitingNCT06102824

Guangdong Provincial People's HospitalAdvanced Breast Cancer, HER2-negative Breast Cancer

Start: 2024-10-01End: 2028-06-30Target: 252Updated: 2024-11-25

Phase 3

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

CompletedNCT00277043

New Mexico Cancer Research AllianceIll-defined Sites, Supportive

Start: 2002-06-30End: 2005-09-30Updated: 2011-09-27

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

TerminatedNCT00849667

MorphotekOvarian Cancer

Start: 2009-04-16End: 2013-04-12Updated: 2022-12-30

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Active, not recruitingNCT02441933

Yonsei UniversityBreast Cancer

Start: 2015-09-01End: 2025-06-30Updated: 2024-06-04

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Active, not recruitingNCT04784715

AstraZenecaBreast Cancer; HER2-positive; Metastatic

Start: 2021-04-26End: 2029-12-30Updated: 2026-02-20

Unknown Phase

Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)

Sun Yat-sen UniversityCervical Cancer

Start: 2015-11-30End: 2025-11-30Target: 60Updated: 2021-01-07

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

TerminatedNCT03393741

University of Wisconsin, MadisonBreast Cancer, Breast Neoplasms

Start: 2018-01-29End: 2024-02-11Updated: 2024-06-25

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

CompletedNCT04920747

Centre Hospitalier Universitaire de BesanconDocetaxel, HER2-positive Gastric Cancer, Metastatic Cancer +1

Start: 2021-04-01End: 2021-05-31Updated: 2021-06-10

Related Papers

Abstract RF6-07: Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study

Clinical Cancer Research2026-02-17

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

2025-10-29

Abstract P1-09-12: Comparative Analysis of the Oncotype DX Breast Recurrence Score® assay for Neoadjuvant Letrozole/Abemaciclib versus Chemotherapy in Stage II-III, Ki67≥20%, HR+/HER2- Breast Cancer: Insights from the GEICAM/CARABELA Trial

Clinical Cancer Research2025-06-13

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Journal of Clinical Oncology2025-06-0419 citations

Pyrotinib and Nab‐Paclitaxel in <scp>HER2</scp>‐Positive Breast Cancer (<scp>PANHER</scp> Trial): A Prospective, Single‐Arm, Phase <scp>II</scp> Trial

Cancer Science2025-04-22

A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.

Journal of Clinical Oncology2024-06-055 citations

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

2024-06-0282 citations

Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.

Journal of Clinical Oncology2024-05-293 citations

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).

2024-05-203 citations

112MO Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial

ESMO Open2024-05-012 citations

Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial

Nature Communications2023-12-1419 citations

Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles

PLoS Biology2023-10-2620 citations

Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer

JNCI Journal of the National Cancer Institute2023-05-1114 citations

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

Frontiers in Immunology2023-03-0716 citations

Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)

Cancer Research2023-03-015 citations

Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors.

Journal of Clinical Oncology2023-02-20

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Cancer Discovery2022-10-1896 citations

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.

2022-08-1192 citations

Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.

Journal of Clinical Oncology2022-06-012 citations

23 more papers not shown